Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 339

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma

Martin, Peter, Chadburn, Amy, Christos, Paul, Weil, Karen, Furman, Richard R., Ruan, Jia, Elstrom, Rebecca, Niesvizky, Ruben, Ely, Scott, DiLiberto, Maurizio, Melnick, Ari, Knowles, Daniel M., Chen-Kiang, Selina, Coleman, Morton, Leonard, John P.·2009·Journal of Clinical Oncology

Abstract

Purpose: Treatment of mantle-cell lymphoma (MCL) is nonstandardized, though patients are commonly treated immediately at diagnosis. Because data on observation, or “watch and wait,” have not been previously reported, we analyzed the outcome of deferred initial therapy. Patients and Methods: Inclusion criteria in this retrospective analysis were a diagnosis of MCL between 1997 and 2007 and known date of first treatment. Hospital and research charts were reviewed for prognostic and treatment-related information. Date of death was derived from hospital records and confirmed using an online Social Security death index. Results: Of 97 patients with MCL evaluated at Weill Cornell Medical Center, 31 patients (32%) were observed for more than 3 months before initial systemic therapy, with median time to treatment for the observation group of 12 months (range, 4 to 128 months). The observation group (median follow-up, 55 months) had a median age of 58 years (range, 40 to 81 years). Prognostic factors in assessable patients included advanced stage (III/IV) in 75%, elevated lactate dehydrogenase in 25%, and intermediate- or high-risk Mantle Cell International Prognostic Index in 54%. Better performance status and lower-risk standard International Prognostic Index scores were more commonly present in those undergoing observation. Although time to treatment did not predict overall survival in a multivariate analysis, the survival profile of the observation group was statistically superior to that of the early treatment group (not reached v 64 months, P = .004). Conclusion: In selected asymptomatic patients with MCL, deferred initial treatment (“watch and wait”) is an acceptable management approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2008.19.6121

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 339

Metadata

Authors
Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R. R., Ruan, J., Elstrom, R., Niesvizky, R., Ely, S., DiLiberto, M., Melnick, A., Knowles, D. M., Chen-Kiang, S., Coleman, M., & Leonard, J. P.
Venue
Journal of Clinical Oncology
Published
2009-03-10
Volume
27
Issue
8
Pages
1209-1213
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2001178238
Cited by
339
References
19
FWCI
18.09
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2008.19.6121
The paper
Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R. R., Ruan, J., Elstrom, R., Niesvizky, R., Ely, S., DiLiberto, M., Melnick, A., Knowles, D. M., Chen-Kiang, S., Coleman, M., & Leonard, J. P. (2009). Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.19.6121

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.